Table 8.
Mean (SD) glucose AUEC1–5 after an oral glucose tolerance test at baseline and after administration of oral empagliflozin doses (2.5–100 mg)
| Empagliflozin dose | Number of patients | Mean (SD) glucose AUEC1–5 (mg h/dL) | ||
|---|---|---|---|---|
| Baseline (day −1) | Day 9 | Change from baseline to day 9 (%) | ||
| Placebo | 12a | 970 (197) | 832 (179) | 14.2 |
| 2.5 mg qd | 9 | 927 (274) | 713 (216) | 23.1 |
| 10 mg qd | 9b | 903 (201) | 655 (144) | 27.5 |
| 25 mg qd | 9 | 882 (175) | 679 (109) | 23.0 |
| 100 mg qd | 9 | 1,060 (225) | 817 (126) | 22.9 |
Data from the treated analysis set (n = 48)
AUEC 1–5 area under the 24-h glucose concentration–time curve 1-5h, SD standard deviation
a n = 11 on day 9
b n = 8 on day 9